Brought to you by 
Clinigen gets rights to Novartis' Cardioxane
17 Jun 2014
Executive Summary
Specialty pharmaco Clinigen Group PLC has acquired Novartis AG’s cancer drug Cardioxane (dexrazoxane) for $33mm in cash, payable in two tranches. Clinigen will now assume responsibility for manufacturing, registration, distribution, and commercialization of the product in territories where marketing authorizations exist, including European, Asian, and Latin American countries.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com